Butyrate and Inflammation: What Researchers Are Finding
Share
By Brandon, founder of Ozzi · Published August 2, 2026 · Updated October 31, 2026
Why are researchers interested in butyrate and inflammation?
Researchers are interested in butyrate and inflammation because two early human trials saw inflammation markers fall.
Inflammation is the immune system's alarm. When it stays switched on at a low level for years, it shows up in blood tests and travels with heart disease, diabetes and joint trouble. Researchers want a safe, food-based way to turn the dial down.
We sell a butyrate supplement, which is why we read this research closely.
What is the theory behind butyrate and inflammation?
The theory is that butyrate reaches immune cells and changes which genes they switch on, so they send out fewer alarm signals. Fewer signals should mean lower inflammation markers in the blood. Here is the chain, step by step.
There is a side road too. Butyrate feeds the cells that form the gut barrier, and a tighter barrier should let less bacterial debris into the blood. In a human trial of 146 post-menopausal women, 570 mg of sodium butyrate a day for 12 weeks lowered two blood markers of a leaky gut (Qaisar 2025). More on that in leaky gut and inflammation.
Parts of this chain are still theory in people.
What have human studies of butyrate and inflammation found?
In early human trials, butyrate lowered the blood inflammation marker CRP in adults with active colitis and in adults with type 2 diabetes, and it lowered the immune signal IL-6 in children with obesity. Other trials saw no change, so larger trials are the next step.
The colitis trial is the clearest. 36 adults with active ulcerative colitis took sodium butyrate capsules or placebo for 12 weeks alongside their usual medicine. Their hs-CRP fell by about 0.4 mg/L on butyrate and rose by about 0.5 on placebo. Fecal calprotectin fell by 134 points while placebo rose by 52, and sleep and quality of life improved (Firoozi 2024).
The children's trial ran longest. 54 children with obesity, ages 5 to 17, took sodium butyrate (20 mg per kilo a day, up to 800 mg) or placebo for 6 months with standard care. IL-6 fell by about 4.8 points more than placebo. Insulin and the insulin-resistance score fell too, and waistlines shrank by about 5 cm more (Coppola 2022).
In 60 adults with type 2 diabetes, 600 mg of sodium butyrate a day for 45 days brought hs-CRP down from 4.3 to 3.0 mg/L. The placebo group drifted up. Diastolic blood pressure came down as well. Some groups also took a prebiotic fiber, and the groups did not start at the same CRP level (Roshanravan 2017).
| Study | Who, and what they took | What improved |
|---|---|---|
| Firoozi 2024 | 36 adults, active colitis; capsules; 12 weeks | CRP and gut marker; sleep |
| Coppola 2022 | 54 children with obesity; up to 800 mg a day; 6 months | IL-6, insulin, waist size |
| Roshanravan 2017 | 60 adults, type 2 diabetes; 600 mg a day; 45 days | CRP; diastolic blood pressure |
| Karłowicz 2025 | 98 adults, colitis; 600 mg a day; 8 weeks | Gut marker; remission rate |
| Qaisar 2025 | 146 women after menopause; 570 mg a day; 12 weeks | Leaky-gut markers; grip strength |
How could the research on butyrate and inflammation play out?
Bigger trials could confirm the early drops in CRP and IL-6 with butyrate, or the effect could prove smaller than hoped, because the liver removes most of the butyrate you swallow.
If it works
Three things would have to go right. First, bigger and longer trials would need to confirm the CRP and IL-6 drops seen so far. Those came from groups of 36 to 98 people over 6 weeks to 6 months. Second, the effect would need to show up in people without a diagnosed illness. Third, a form and a dose that an ordinary person can take daily would need to deliver enough butyrate to the gut wall and the bloodstream.
If it falls short
The liver takes most of it. Butyrate taken by mouth goes first to the liver, which removes most of it. In 19 men who took 4 g of sodium butyrate a day for 4 weeks, fasting blood butyrate did not rise (Bouter 2018). So the share that reaches immune cells in the blood may be small.
Some trials saw no change. In 53 adults with type 1 diabetes, 3.6 g a day for 12 weeks moved neither the gut marker nor CRP (Tougaard 2022). In 181 adults with fatty liver disease, 1,000 mg a day for 12 weeks left CRP and IL-6 where they were (Mitrović 2025).
Blood pressure needs watching. In 23 adults with high blood pressure who paused their medication, 4 g of sodium butyrate a day for 4 weeks raised daytime blood pressure. The top number rose about 10 points more than on placebo (Verhaar 2024). The placebo held the same amount of sodium. If you have high blood pressure, show this trial to your doctor before you take butyrate.
The trials are small and the doses are large. Most used 600 mg to 4 g a day, in people who already had a condition and raised markers. A healthy adult with a normal CRP has not been tested yet.
Butyrate supplements are not a treatment for colitis, Crohn's disease, diabetes or high blood pressure. If you have one of these, work with your doctor.
How do you get more butyrate?
The first way to get more butyrate is to eat more fiber. Fiber from beans, oats, whole grains and vegetables is what your gut bacteria turn into butyrate. How to increase butyrate naturally covers the foods, and our short-chain fatty acids guide explains the family.
If you want a supplement, know the forms. Sodium butyrate is the salt most trials used, and sodium is about 21% of its weight. Tributyrin is butyrate bound to a fat. L-lysine butyrate binds it to an amino acid, with no sodium; it has a small human absorption study behind it and no outcome trial yet. The comparison is in best form of butyrate.
If gut symptoms are your reason for reading, see butyrate for IBS and bloating. The rest of the research lives in the butyrate research hub, including butyrate and liver health. And if you have high blood pressure or a bowel disease, talk with your doctor before you start anything.

The form we chose
Ozzi BIOMEnd Butyrate
1,000 mg of BIOMEnd L-lysine butyrate per daily serving of 4 capsules. No sodium carrier and no added oils. 112 capsules, 28 servings per bottle. It is a dietary supplement, and it has not been tested for any of the conditions discussed on this page.
See the butyrate supplement →Frequently asked questions
How does butyrate decrease inflammation?
The theory is that butyrate blocks HDAC enzymes inside immune cells, turns down the NF-kB switch that drives inflammatory genes, and raises the regulatory T cells that calm the immune system. Early research supports each step. In people, the NF-kB step has been seen in colitis patients given butyrate enemas.
Does butyrate help with histamine intolerance?
Early lab research found butyrate reduced the release of histamine from mast cells, the cells behind allergic reactions (Folkerts 2020). Butyrate itself contains no histamine. The next step is a human trial, and none has been run yet.
About the author
Brandon is the founder of Ozzi. He reads the research himself and writes it up in plain English, with the sources listed so you can check them. More at Brandon's author page.
This article is for educational purposes and isn't medical advice. It describes published research on butyrate, not the effects of any Ozzi product. Ozzi products are dietary supplements and are not intended to diagnose, treat, cure, or prevent any disease. Talk to your healthcare provider before starting any supplement, especially if you have a medical condition or take medication.
References
- Firoozi D, et al. Effects of short-chain fatty acid-butyrate supplementation on expression of circadian-clock genes, sleep quality, and inflammation in patients with active ulcerative colitis: a double-blind randomized controlled trial. Lipids Health Dis. 2024. PubMed 39003477
- Coppola S, et al. Therapeutic effects of butyrate on pediatric obesity: a randomized clinical trial. JAMA Netw Open. 2022. PubMed 36469320
- Chang PV, et al. The microbial metabolite butyrate regulates intestinal macrophage function via histone deacetylase inhibition. Proc Natl Acad Sci U S A. 2014. PubMed 24390544
- Lührs H, et al. Butyrate inhibits NF-kappaB activation in lamina propria macrophages of patients with ulcerative colitis. Scand J Gastroenterol. 2002. PubMed 11989838
- Furusawa Y, et al. Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells. Nature. 2013. PubMed 24226770
- Qaisar R, et al. Butyrate improves handgrip strength and physical performance by reducing intestinal leak in post-menopausal women, a randomized controlled trial. Eur J Nutr. 2025. PubMed 40167641
- Roshanravan N, et al. The effects of sodium butyrate and inulin supplementation on angiotensin signaling pathway via promotion of Akkermansia muciniphila abundance in type 2 diabetes; a randomized, double-blind, placebo-controlled trial. J Cardiovasc Thorac Res. 2017. PubMed 29391930
- Karłowicz K, et al. Efficacy of microencapsulated sodium butyrate as add-on therapy in inducing remission in patients with mild-to-moderate ulcerative colitis: results from a multi-center, double-blind, randomized, placebo-controlled study. Med Sci Monit. 2025. PubMed 41422374
- Panufnik P, et al. Effect of microencapsulated sodium butyrate on abdominal symptoms and carbohydrate metabolism in patients with type 2 diabetes: a randomized placebo-controlled trial. Sci Rep. 2026. PubMed 41974937
- Testa R, et al. Targeting weight loss and blood glucose control with oral sodium butyrate in overweight/obese adults with and without type 2 diabetes: a proof-of-concept randomized controlled trial. Clin Nutr. 2026. PubMed 41880673
- Bouter K, et al. Differential metabolic effects of oral butyrate treatment in lean versus metabolic syndrome subjects. Clin Transl Gastroenterol. 2018. PubMed 29799027
- Tougaard NH, et al. Effects of butyrate supplementation on inflammation and kidney parameters in type 1 diabetes: a randomized, double-blind, placebo-controlled trial. J Clin Med. 2022. PubMed 35806857
- Mitrović M, et al. Exploring the potential of oral butyrate supplementation in metabolic dysfunction-associated steatotic liver disease: subgroup insights from an interventional study. Int J Mol Sci. 2025. PubMed 40565024
- Verhaar BJH, et al. Effects of oral butyrate on blood pressure in patients with hypertension: a randomized, placebo-controlled trial. Hypertension. 2024. PubMed 39034917
- Folkerts J, et al. Butyrate inhibits human mast cell activation via epigenetic regulation of FcεRI-mediated signaling. Allergy. 2020. PubMed 32112426
